

20 May 2025

**LungLife AI, Inc.**  
(the "Company" or "LungLife")

**Result of Special Meeting**  
**Update on Cancellation and License and Distribution Agreement**

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at the Special Meeting held earlier today, both resolutions put to Stockholders were duly passed.

The proxy votes cast in respect of the Resolutions are as follows:

No.	Summary of Resolution	For*	%	Against	%	Withheld**
1	To authorise, in accordance with Rule 41 of the AIM Rules for Companies, the cancellation of the admission to trading on AIM of the Common Shares of the Company.	18,092,184	95.2%	921,240	4.8%	1,969,934
2	To authorise the transaction between the Company and Circulogene Theranostics, Inc. and the related agreements on the terms and conditions and as described in the Circular published by the Company on 29 April 2025.	20,983,358	100%	Nil	0%	Nil

\* Includes those votes giving the Chairman discretion.

\*\*A vote withheld is not a vote in law and is therefore not counted towards the proportion of votes "for" or "against" the Resolutions.

**Update on the cancellation of admission of the Common Shares to trading on AIM**

**As a result of the passing of the Cancellation Resolution, trading in the Company's Common Shares on AIM will be cancelled at 7.00 a.m. on 29 May 2025. Stockholders are therefore reminded that the last day of dealings in the Company's Common Shares on AIM will be 28 May 2025.**

**Update on Exclusive License and Distribution Agreement with Circulogene Theranostics.**

Following the passing of the Agreement Approval Resolution, the Company is proceeding to seek Completion of the Agreement. The Company is working with the relevant stakeholders to satisfy the Required Consents to allow for Completion and at present the Board anticipates that Completion should take place in Q2 2025, although this is expected to be following the date of Cancellation.

Further details of the Agreement and the Cancellation, can be found in the announcement issued by the Company on 29 April 2025 and the Circular which was sent to Stockholders on 29 April 2025 and is available on the Company's website at: <https://lunglifeai.com/investors/financial-information-documents-presentations/>.

**Capitalised terms used in this announcement shall have the meanings given to such terms in the announcement issued by the Company on 29 April 2025 and in the Circular unless otherwise defined herein.**

For further information please contact:

**LungLife AI, Inc.**  
Paul Pagano, CEO  
David Anderson, CFO

[www.lunglifeai.com](http://www.lunglifeai.com)  
via investors@lunglifeai.com

**Allenby Capital Limited**  
Nominated Adviser and Joint Broker  
Alex Brearley / Lauren Wright - Corporate Finance  
Matt Butlin / Guy McDougall - Equity Sales & Corporate Broking

Tel: +44 (0)20 3328 5656  
info@allenbycapital.com

### **About LungLife**

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit [www.lunglifeai.com](http://www.lunglifeai.com).

Our Purpose is to be a driving force in the early detection to lung cancer. And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMURRNRVWUVUAR